- Coherus launches UdenycaTM, a pegfilgrastim biosimilar, in the United States.
- Pfizer launches Retacrit®, an epoetin alfa biosimilar, in the United States.
- FDA approves the first rituximab biosimilar, although it has not yet launched in the United States.
- European Medicines Agency approves third, fourth, and fifth pegfilgrastim biosimilars and a fifth trastuzumab biosimilar, while